Advertisement

Mobile Health for Diagnosis-PixoTest HbA1c POCT System

  • Shi-Yann Cheng
  • Tung-Meng Tsai
  • Yen-Yu Chen
  • Po-Jung Lai
  • Tai-I Chen
  • Chiung-Wen Hsu
  • Chieh-Hsiao ChenEmail author
Original Article
  • 4 Downloads

Abstract

Objectives

Glycated hemoglobin (HbA1c) has been recommended as a standard indicator of long-term glycemic control for diabetic and non-diabetic patients, within the in vitro diagnostic (IVD) industry that is focused on the development of point-of-care (POC) methods with improved operational convenience and shorter measurement time. In this study, we evaluated the measurement accuracy performance of a recently commercialized POC HbA1c analyzer, PixoTest POCT System (iXensor Co., Ltd.) that is portable, intuitive and wireless data transmission enabled.

Materials and Methods

For PixoTest POCT accuracy evaluation, TOSOH G7 Analyzer (TOSOH Bioscience GmbH) was used as a reference method and performed in accordance with CLSI EP 09-A3 guidelines. This study enrolled one hundred and twenty (120) subjects from three clinical sites (40 subjects each), administered through nine (9) trained operators (total) performed under manufacturer’s protocol using three reagent lots per blood sample (capillary & venous). Linear regression, bias plot and other statistical analyses were extrapolated from the test data.

Results

Passing-Bablok regression analysis of the data between PixoTest POCT System and TOSOH G7 Analyzer with the venous blood showed a slope of 1.03 and an intercept of − 0.1 and a correlation coefficient of 0.99. The results for capillary blood showed a slope of 1.01 and an intercept of − 0.04 and a correlation coefficient of 0.99.

Conclusion

The PixoTest POCT System’s performance is similar to TOSOH G7 Analyzer in accuracy and linearity. Therefore, the system’s HbA1c test capability is ideal for the management of chronic disease, as a user convenient and efficient POC solution.

Keywords

Point-of-care (POC) testing Glycated hemoglobin (HbA1c) PixoTest 

References

  1. 1.
    American Diabetes Association. (2014). Standards of medical care in diabetes—2014. Diabetes Care, 37(Suppl. 1), S14–S80.CrossRefGoogle Scholar
  2. 2.
    Zhao, W., Katzmarzyk, P. T., Horswell, R., Wang, Y., Johnson, J., & Hu, G. (2014). HbA1c and coronary heart disease risk among diabetic patients. Diabetes Care, 37(2), 428–435.  https://doi.org/10.2337/dc13-1525.CrossRefGoogle Scholar
  3. 3.
    Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016). Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomarker Insights, 11, 95–104.CrossRefGoogle Scholar
  4. 4.
    Weykamp, C. (2013). HbA1c: A review of analytical and clinical aspects. Annals Laboratory Medicine, 33(6), 393–400.CrossRefGoogle Scholar
  5. 5.
    Cagliero, E., Levina, E. V., & Nathan, D. M. (1999). Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care, 22(11), 1785–1789.CrossRefGoogle Scholar
  6. 6.
    Ferenczi, A., Reddy, K., & Lorber, D. L. (2001). Effect of immediate hemoglobin A1c results on treatment decisions in office practice. Endocrine Practice, 7(2), 85–88.CrossRefGoogle Scholar
  7. 7.
    Miller, C. D., Barnes, C. S., Phillips, L. S., Ziemer, D. C., Gallina, D. L., Cook, C. B., et al. (2003). Rapid A1c availability improves clinical decision-making in an urban primary care clinic. Diabetes Care, 26(4), 1158–1163.CrossRefGoogle Scholar
  8. 8.
    Little, R. R., Lenters-Westra, E., Rohlfing, C. L., & Slingerland, R. (2011). Point-of-care assays for hemoglobin A(1c): Is performance adequate? Clinical Chemistry, 57(9), 1333–1334.CrossRefGoogle Scholar
  9. 9.
    Lenters-Westra, E., & Slingerland, R. J. (2010). Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clinical Chemistry, 56(1), 44–52.CrossRefGoogle Scholar
  10. 10.
    Lee, K., Jun, S. H., Han, M., Song, S. H., Park, K. U., Song, W. H., et al. (2015). Performance evaluation of SD A1cCare as a HbA1c analyzer for point-of-care testing. Clinical Biochemistry, 48(9), 625–627.CrossRefGoogle Scholar
  11. 11.
    National Institute for Health Research. (2016). Point-of-care HbA1c tests—Diagnosis of diabetes. Horizon Scan Report 0044.Google Scholar
  12. 12.
    Leon, B. M., & Maddox, T. M. (2015). Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World Journal of Diabetes, 6(13), 1246–1258.  https://doi.org/10.4239/wjd.v6.i13.1246.CrossRefGoogle Scholar
  13. 13.
    Nathan, D. M., Bayless, M., Cleary, P., et al. (2013). Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Advances and contributions. Diabetes, 62(12), 3976–3986.  https://doi.org/10.2337/db13-1093.CrossRefGoogle Scholar

Copyright information

© Taiwanese Society of Biomedical Engineering 2019

Authors and Affiliations

  1. 1.School of MedicineChina Medical UniversityTaichung CityTaiwan
  2. 2.iXensor Co., Ltd.Taipei CityTaiwan
  3. 3.Department of Nursing and Department of UrologyChina Medical University Beigang HospitalYunlin CountyTaiwan

Personalised recommendations